Case report

Solitary skull metastasis in presumed early stage cervical cancer

Brianne M. Morgan a, *, Matthew Bierowski a, Amalia Brawley b, Ayodele G. Ayoola c, Joshua Kesterson b

a Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States
b Department of Obstetrics and Gynecology, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, United States
c Department of Medicine, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, United States

* Corresponding author.
E-mail address: bmorgan4@pennstatehealth.psu.edu (B.M. Morgan).

https://doi.org/10.1016/j.gore.2021.100889
Received 12 September 2021; Received in revised form 2 November 2021; Accepted 8 November 2021

1. Background

Cervical cancer is the most common reproductive malignancy in women worldwide, causing 311,000 deaths in 2018 (Arbyn et al., 2020). Its pattern of spread is typically direct and/or contiguous invasion, thus the majority of women present with regional disease (Thanapprapasr et al., 2010). Isolated skull metastases are exceedingly rare in squamous cell carcinoma of the cervix, especially early stage (Zilberlicht et al., 2010). Isolated skull metastases are exceedingly rare in squamous cell carcinoma of the cervix, especially early stage (Zilberlicht et al., 2010). Isolated skull metastases are exceedingly rare in squamous cell carcinoma of the cervix, especially early stage (Zilberlicht et al., 2010). Isolated skull metastases are exceedingly rare in squamous cell carcinoma of the cervix, especially early stage (Zilberlicht et al., 2010). Isolated skull metastases are exceedingly rare in squamous cell carcinoma of the cervix, especially early stage (Zilberlicht et al., 2010).

2. Case summary

This is a 56-year-old postmenopausal woman with no previous history of abnormal PAP smears who presented with vaginal bleeding and cervical cytology showing malignant cells of either squamous or glandular origin. This prompted further imaging, including MRI, which demonstrated a 4 × 4.5 cm cervical mass. The patient underwent a radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy. Final pathology demonstrated a poorly differentiated squamous cell carcinoma with deep stromal invasion and lymphovascular space invasion. The surgical margins were negative and all pelvic lymph nodes were negative for malignancy, meeting classification as stage IB2. Based on this pathology, the patient met Sedlis criteria for external pelvic radiation following the hysterectomy with concurrent chemotherapy with a platinum-based agent. Her post-operative course was complicated by a pulmonary embolus which delayed port placement for chemotherapy. Prior to initiation of chemotherapy and seven weeks following surgery, the patient was noted to have a palpable lesion on her forehead, which was painless, but visually distressing. Ultrasound confirmed a 3 cm mass of the frontal calvarium. Follow up CT demonstrated an enhancing soft tissue density with heterogeneous lucency measuring 12 × 7 mm and destruction of the underlying calvarium, consistent with an aggressive process (Fig. 1). Fine needle aspiration confirmed metastatic poorly differentiated carcinoma, consistent with metastases. Bone scan demonstrated no evidence of other bony metastatic disease.

Treatment began with six cycles of 175 mg/m² paclitaxel, 50 mg/m² cisplatin, and 50 mg/kg bevacizumab IV. After completion of chemotherapy regimen, chemoradiation and 12 cycles of monthly SubQ 120 mg denosumab were initiated. The patient underwent external beam radiation therapy (EBRT) consisting of 220 cGy/25Fx (5500 cGy total) to the pelvis and 300 cGy/10Fx (2700 cGy total) to the skull with concurrent weekly 40 mg/m² cisplatin. Only three out of seven cycles of cisplatin was given due to severe nausea, dehydration, and acute renal failure, requiring a hospital admission. Interstitial brachytherapy Ir-192 15 Gy/3Fx was completed following chemoradiation which was tolerated well. Skull metastasis persisted and a treatment plan of six cycles of 175 mg/m² paclitaxel, 50 mg/m² cisplatin, and 15 mg/kg bevacizumab IV was initiated. Due to persistent peripheral neuropathy, paclitaxel was reduced 50% by the second cycle and the entire regimen was discontinued before the third cycle. Maintenance 15 mg/kg bevacizumab was begun. Post-treatment PET CT showed no evidence of locally recurrent disease or metabolically active metastatic disease. Following therapy, the patient was doing well with no clinical evidence of disease.

Keywords
Cervical carcinoma
Skull metastasis
Denosumab
inhibiting bone resorption (Hanley et al., 2012). Denosumab reduces
RANKL, blocking osteoclast maturation and function, therefore
Denosumab is a subcutaneous injected monoclonal antibody that binds
squamous cell carcinomas (Gül et al., 2016; Scagliotti et al., 2012).

External carotid artery (Agarwal et al., 2002). This case report further
spread allows bloodstream seeding that transports the tumor to the
cervical carcinoma presenting with new onset head-related symptoms
Gül, G., Sendur, M.A.N., Aksoy, S., et al., 2016. A comprehensive review of denosumab
metastasis, Gül et al. (2016) and Scagliotti et al. (2012) found that it was
associated with improved median survival in patients with squamous
cell carcinoma of the lung with bone metastasis. Although there are no
reports in the literature looking at the outcomes of using denosumab in
patients with bone metastasis specifically from cervical cancer, van Dam
et al. (2019) hypothesize that inhibition of RANK-RANKL interaction
may not only be beneficial with bone metastasis, but also with dis-
rupting cell–cell signaling of the primary cervical carcinoma. Citing
prior experiments, they discuss how RANKL is directly secreted by cer-
vical cells and may be used as a method by tumors to create an immune-
suppressive environment, with its inhibition potentially reversing this
effect (Demoulin et al., 2015). The role of RANKL signaling in cervical
carcinoma progression is further supported by experiments demon-
strating a positive correlation between RANKL mRNA levels and
increasing tumor burden, lymph nodes metastasis, and clinical stage (Ma
et al., 2017). The long-term success of this treatment regimen warrants
further investigation.

In conclusion, patients with new onset headaches or bony skull
protuberances with a history of cervical carcinoma should be evaluated
for evidence of metastasis. Early hematologic spread is possible, as
evidenced in this case with distal metastasis with no lymphatic
involvement. In the case of bony metastasis from primary cervical car-
cinoma, providers should advise the addition of denosumab to treatment
regimen as it may serve a bone-stabilizing and potential therapeutic
effect.

3. Discussion

Hematogenous spread of cervical cancer is usually an indicator of late stage
disease with the liver, lung, and bones being the most frequent
location of distant metastases (Thanapprapasr et al., 2010; Gardner,
et al., 2020; Agarwal et al., 2002). While there are case reports of iso-
lated metastases to distant sites of the body from cervical cancer, iso-
lated skull metastases are exceedingly rare with few published cases.
Zilberlicht et al. (2015) reported a single skull metastasis in a 58-year-
old woman with stage IIb cervical carcinoma. Diaz et al. (2019) re-
ported a single skull metastasis in a 41-year old female 18 months after
treatment for stage IIIb cervical cancer.

There are estimated to be around a dozen cases of skull metastasis
from cervical cancer in the literature with the majority of these reports
occurring in later stage disease, following the hypothesis of lymphatic
spread prior to hematologic spread (Zilberlicht et al., 2015; Diaz et al.,
2019). However, both Zilberlicht et al. (2015) and Diaz et al. (2019)
demonstrate there are very rare cases in which hematologic spread
may occur concurrently. One current explanation is that local venous
spread allows bloodstream seeding that transports the tumor to the
external carotid artery (Agarwal et al., 2002). This case report further
supports the possibility of early hematologic spread.

The most common presenting symptoms of a skull metastasis include
a noticeable scalp mass, headache, and local bony tenderness (Zilber-
licht et al., 2015). In this case, the patient presented with a skull
mass only seven weeks following diagnosis of cervical carcinoma, which
allowed for efficient diagnosis of the skull metastasis. However, given
there are reports of isolated skull metastasis several years after remis-
sion, it is imperative that the physician maintains a high index of sus-
picion for metastatic disease for any patient with a past history of
cervical carcinoma presenting with new onset head-related symptoms
(Diaz et al., 2019; Baid et al., 1992).

This patient’s systemic cytotoxic and radiation therapy was supple-
mented with denosumab due to its documented success in prolonging
survival and preventing the progression of bone metastasis from primary
squamous cell carcinomas (Gül et al., 2016; Scagliotti et al., 2012).
Denosumab is a subcutaneous injected monoclonal antibody that binds to
RANKL, blocking osteoclast maturation and function, therefore
inhibiting bone resorption (Hanley et al., 2012). Denosumab reduces
skeletal-related events in patients with solid tumors and bone

4. Consent

Written informed consent was obtained from the patient for publi-
cation of this case report and accompanying images. A copy of the
written consent is available for review by the Editor-in Chief of this
journal upon request.

Declaration of Competing Interest

The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influence
the work reported in this paper.

References

Agarwal, U., Dahiya, P., Chauhan, A., et al., 2002. Scalp metastasis in carcinoma of the
uterine cervix: a rare entity. Gynecol. Oncol. 87 (3), 310–312. https://doi.org/
10.1006/gyno.2002.6829.

Arbyn, M., Weiderpass, E., Bruni, L., de Sanjose, S., Saraiya, M., Ferlay, J., Bray, F., 2020.
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide
analysis. Lancet Glob. Health 8 (2), e191–e203.

Baid, B.L., Kumar, L., Chander, S., et al., 1992. Bone metastases in the patients of
carcinoma cervix, Indian J. Cancer 29 (2), 71–75.

Demoulin, S.A., et al., 2015. Cervical (pre)neoplastic microenvironment promotes the
emergence of tolerogenic dendritic cells via RANKL secretion. Oncoimmunology 4
(6), e1008234. https://doi.org/10.2147/OI.S95034.

Diaz, J.F.R., Zelaya, A.H., Rosas, A.M.A., 2019. Scalp and skull bone metastasis in
cervical carcinoma—a rare entity. Ecancer 13, 969. https://doi.org/10.3332/ecancer.
2019.969.

Gardner, A.B., Charo, I.M., Mann, A.K., et al., 2020. Ovarian, uterine, and cervical
cancer patients with distant metastases at diagnosis: most common locations and
outcomes. Clin. Exp. Metastasis 37 (1), 107–113. https://doi.org/10.1007/s10585-
019-10007-0.

Gül, G., Sendur, M.A.N., Aksoy, S., et al., 2016. A comprehensive review of denosumab
for bone metastasis in patients with solid tumors. Curr. Med. Res. Opin. 32 (1),
133–145.

Hanley, D.A., Adachi, J.D., Bell, A., Brown, V., 2012. Denosumab: mechanism of action
and clinical outcomes. Int. J. Clin. Pract. 66 (12), 1139–1146. https://doi.org/
10.1111/jcpr.12022.

Ma, D., et al., 2017. KLF5 promotes cervical cancer proliferation, migration and invasion
in a manner partly dependent on TNFRSF11a expression. Sci. Rep. 7 (1) https://doi.
org/10.1038/s41598-017-15979-1.

Scagliotti, G.V., Hirsh, V., Siena, S., et al., 2012. Overall survival improvement in
patients with lung cancer and bone metastases treated with denosumab versus
zoledronic acid: subgroup analysis from a randomized phase 3 study. J. Thorac.
Oncol. 7 (12), 1823–1829.
Thanapprapasr, D., Narthanarung, A., Likittanasombut, P., et al., 2010. Bone metastasis in cervical cancer patients over a 10-year period. Int. J. Gynecol. Cancer 20 (3), 373–378.

van Dam, P.A., Verhoeven, Y., Jacobs, J., et al., 2019. RANK-RANKL signaling in cancer of the uterine cervix: A review. Int. J. Mol. Sci. 20 (9), 2183. https://doi.org/10.3390/ijms20092183.

Zilberlicht, A., Voldavsky, E., Lavie, O., et al., 2015. Prolonged survival in a patient with isolated skull recurrence of cervical carcinoma – Case report and review of the literature. Gynecol. Oncol. Rep. 11, 20–22.